|
Placebo group (n=6)
|
SR 27897B group (n=12)
|
Characteristics of the patients (mean (SD)): |
Age (y) | 56 (8) | 56 (10.5) |
Sex (M/F) | 4/2 | 4/9 |
Disease duration (y) | 17.3 (6) | 12.5 (6) |
Duration of levodopa therapy (y) | 16 (6) | 10.1 (6) |
Daily levodopa dose (mg) | 883 (370) | 887 (415) |
Hoehn and Yahr score (on/off) | 2.3 (0.5)/3.8 (0.8) | 2.2 (0.8)/3.7 (0.9) |
|
Effect on motor disability (mean (SEM)) | Day 1 | Day 14 | Day 1 | Day 14 |
UPDRS III | off state | 52.5 (7.3) | 57 (8.1) | 47.6 (4.8) | 45 (4.6) |
| on state | 19.8 (3.6) | 17.3 (2.9) | 14.1 (2.3) | 13.1 (2.4) |
Motor improvement (%)1-151
| 61.8 (4.5) | 67.1 (6.2) | 68.4 (4.3) | 72.6 (3.0) |
Delay of dopaminergic action (min) | 13.2 (3.4) | 10.0 (1.4) | 10.1 (1.2) | 12.8 (2.5) |
Duration of the on phase (min) | 46.7 (5.8) | 55.7 (6.9) | 65.9 (4.9) | 60.3 (6.4) |
Effect on dyskinesia (mean (SEM)): |
Severity of the dyskinesia (score/min)1-150
| 3.5 (0.8) | 3.9 (1.1) | 3.6 (0.6) | 3.1 (0.6) |